Combination Therapy Shows Promise in Fighting Neuroblastoma
A study by a multidisciplinary team of researchers from The Saban Research Institute of Children’s Hospital Los Angeles sheds further light on the role of the cytokine TGFB1 in the growth of neuroblastoma and suggests the possibility for a small molecule drug/antibody combinatorial therapy to treat this cancer.
Neuroblastoma (NB) is a type of solid cancer that arises from nerve tissues. It is the most common type of childhood cancer with nearly half of its incidence in children under two years of age and accounts for 15 percent of all childhood cancer deaths. Currently available therapy involves the use of an antibody called dinutuximab which targets a type of modified carbohydrate sugar (GD2) found to be expressed at high levels in NB tumors. However, this antibody-based treatment is often not sufficient to prevent cancer relapse.
Click here to read more.
Second International Brain Mapping Course
April 26-27, 2018; New Orleans
Surgical Approaches to Skull Base
April 26-28, 2018; St. Louis, MO
2018 AANS Annual Scientific Meeting
April 28-May 2, 2018; New Orleans
Goodman Oral Board Preparation Course
May 2-4, 2018; Phoenix
2018 Advanced Endoscopic Skull Base and Pituitary Surgery
June 1-2, 2018; New York